Participant flow

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer · Source last updated 2026-01-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cabozantinib: Given PO Pembrolizumab: Given IV

   id

   FG000

   title

   Treatment (Pembrolizumab, Cabozantinib)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         16

      type

      Progressive Disease

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Alternate therapy

   5. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         36

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice